Leggio Gian Marco, Micale Vincenzo, Drago Filippo
Department of Experimental and Clinical Pharmacology, University of Catania Medical School, 95125 Catania, Italy.
Eur Neuropsychopharmacol. 2008 Apr;18(4):271-7. doi: 10.1016/j.euroneuro.2007.07.003. Epub 2007 Sep 4.
Evidence exists for a dopaminergic system dysregulation in mood disorders. In particular, depression may be accompanied by a relative fall of brain dopamine (DA) availability, while the increase of dopamine D2/D3 receptors (D2R/D3R) binding may reflect a compensatory change following primary reduction of mesolimbic DA levels. It is well established that D3Rs, acting as autoreceptors, inhibit DA synthesis and release, although lack of selective compounds have limited the progress in understanding D3Rs role in mood disorders. Aim of this study was to assess the behavioral responses of D3R-deficient (D3(-/-)) mice tested in the forced swim test (FST) and to evaluate their sensitivity to the treatment with different antidepressant drugs. Different groups of mice received one injection of the tricyclic compound, clomipramine (1, 5 and 10 mg/kg) or of one the selective serotonin reuptake inhibitors (SSRIs), paroxetine, sertraline or citalopram (1, 4 and 16 mg/kg), 30 min prior the behavioral test. Vehicle-injected wild type (WT) mice and D3(-/-) animals were used as controls and submitted to the same experimental procedure. In a preliminary experiment, vehicle-injected D3(-/-) mice, but not their littermates, failed to show an increased immobility time in FST as compared to intact controls, suggesting an increased resistance to injection-induced stress in the former. Clomipramine 1 mg/kg failed to affect behavioral responses of both D3(-/-) mice and WT animals. After the 5 mg/kg dose, D3(-/-) and WT mice showed a better performance in FST than vehicle-injected controls, with a lower immobility time exhibited by D3(-/-) mice than that shown by WT animals. No difference was found between WT mice treated with the highest dose of clomipramine (10 mg/kg) and the respective controls, although D3(-/-) mice exhibited a decreased immobility time as compared to vehicle-injected controls. In contrast to WT animals, when treated with 1 mg/kg sertraline and the 4 mg/kg dose of every SSRI D3(-/-) mice exhibited a decreased immobility time in FST in comparison to vehicle-injected controls. Furthermore, 16 mg/kg doses of citalopram, paroxetine or sertraline induced a greater reduction of immobility time in D3(-/-) mice than in WT-treated animals as compared to their respective controls. These data suggest that D3(-/-) mice, as being more resistant to stressful procedure than WT littermates, are more sensitive to antidepressants in FST paradigm than the former. Although the present data do not allow any conclusion on the neurochemical base of this difference, it might be possible that the greater sensitivity to antidepressants depends on a higher DA levels in mesolimbic pathways following the lack of D3Rs.
有证据表明情绪障碍中存在多巴胺能系统失调。特别是,抑郁症可能伴随着脑内多巴胺(DA)可用性的相对下降,而多巴胺D2/D3受体(D2R/D3R)结合的增加可能反映了中脑边缘DA水平原发性降低后的一种代偿性变化。众所周知,D3R作为自身受体,可抑制DA的合成和释放,尽管缺乏选择性化合物限制了对D3R在情绪障碍中作用的理解进展。本研究的目的是评估D3R基因缺陷(D3(-/-))小鼠在强迫游泳试验(FST)中的行为反应,并评估它们对不同抗抑郁药物治疗的敏感性。不同组的小鼠在行为测试前30分钟接受一次三环化合物氯米帕明(1、5和10mg/kg)或一种选择性5-羟色胺再摄取抑制剂(SSRI)、帕罗西汀、舍曲林或西酞普兰(1、4和16mg/kg)的注射。注射溶媒的野生型(WT)小鼠和D3(-/-)动物用作对照,并接受相同的实验程序。在一个初步实验中,注射溶媒的D3(-/-)小鼠,而非它们的同窝小鼠,与完整对照相比,在FST中未表现出不动时间增加,这表明前者对注射诱导的应激具有更高的抵抗力。1mg/kg的氯米帕明未能影响D3(-/-)小鼠和WT动物的行为反应。在5mg/kg剂量后,D3(-/-)和WT小鼠在FST中的表现均优于注射溶媒的对照,D3(-/-)小鼠的不动时间低于WT动物。用最高剂量氯米帕明(10mg/kg)治疗的WT小鼠与各自的对照之间未发现差异,尽管与注射溶媒的对照相比,D3(-/-)小鼠的不动时间有所减少。与WT动物相反,当用1mg/kg舍曲林和4mg/kg剂量的每种SSRI治疗时,D3(-/-)小鼠在FST中的不动时间与注射溶媒的对照相比有所减少。此外,与各自的对照相比,D3(-/-)小鼠中16mg/kg剂量的西酞普兰、帕罗西汀或舍曲林诱导的不动时间减少幅度大于WT治疗动物。这些数据表明,D3(-/-)小鼠比WT同窝小鼠对压力程序更具抵抗力,在FST范式中比前者对抗抑郁药更敏感。尽管目前的数据无法就这种差异的神经化学基础得出任何结论,但对抗抑郁药更高的敏感性可能取决于缺乏D3R后中脑边缘通路中更高的DA水平。